- Trials with a EudraCT protocol (132)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
132 result(s) found for: RNA sequencing.
Displaying page 1 of 7.
EudraCT Number: 2021-001654-65 | Sponsor Protocol Number: PDY16967 | Start Date*: 2021-11-30 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Developpement | |||||||||||||
Full Title: A Phase 2a, open label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD) | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004241-32 | Sponsor Protocol Number: EDOLAS | Start Date*: 2020-02-07 | |||||||||||
Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI | |||||||||||||
Full Title: Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression | |||||||||||||
Medical condition: HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001457-50 | Sponsor Protocol Number: SIL-TH-01 | Start Date*: 2012-05-23 |
Sponsor Name:fUNDACIÓN iNVESTIGACIÓN HOSPITAL RAMÓN Y CAJAL | ||
Full Title: Study on the effect of intravenous silimaryn in the perioperative period of liver transplantation (before, during and after) for the prevention and prognosis of hepatitis C virus reinfection of the... | ||
Medical condition: Patients transplanted for chronic liver disease or hepatocarcinoma relating to C virus being replicated at the time of the OLT (orthotopic liver transplantation). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004213-41 | Sponsor Protocol Number: 5172-048 | Start Date*: 2014-05-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. | |||||||||||||
Full Title: A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection who failed prior Dire... | |||||||||||||
Medical condition: Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000633-14 | Sponsor Protocol Number: SZÚ/01591/2021 | Start Date*: 2021-03-30 | |||||||||||
Sponsor Name:Státní zdravotní ústav | |||||||||||||
Full Title: DYNAMICS OF POSTVACCINATION ANTI- SARS-COV-2 ANTIBODY RESPONSE IN EMPLOYES OF THE NATIONAL INSTITUTE OF PUBLIC HEALTH AND VOLUNTARIES 1-2021 | |||||||||||||
Medical condition: antibody response following vaccine application | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000149-53 | Sponsor Protocol Number: D-STAPH | Start Date*: 2014-05-06 |
Sponsor Name:Karolinska University Hospital, Huddinge | ||
Full Title: ’D-STAPH’ Vitamin D supplementation to persistent carriers of MRSA – A double blind, randomised controlled trial | ||
Medical condition: Persistent MRSA carriers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2023-000052-38 | Sponsor Protocol Number: FOSFO3GCRE | Start Date*: 2023-06-26 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | |||||||||||||
Full Title: Intravenous Fosfomycin in hospitalized patients with complicated urinary tract infections due to Third-generation cephalosporinresistant Enterobacterales. | |||||||||||||
Medical condition: urinary tract infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000358-26 | Sponsor Protocol Number: BETAF-RED | Start Date*: 2022-05-11 | |||||||||||
Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer | |||||||||||||
Full Title: Safety, tolerability, and efficacy of a dose reduction strategy based on bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-infected adults. | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001956-31 | Sponsor Protocol Number: 2015-001956-31 | Start Date*: 2015-06-09 | |||||||||||
Sponsor Name:Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre. | |||||||||||||
Full Title: Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants | |||||||||||||
Medical condition: Patients with chronic hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000127-14 | Sponsor Protocol Number: NCT-2017-0516 | Start Date*: Information not available in EudraCT |
Sponsor Name:Heidelberg University Hospital | ||
Full Title: INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies | ||
Medical condition: This trial investigates a novel combination treatment regimen using immune checkpoint inhibition and epigenetic therapy in children with relapsed/refractory/progressive high-risk solid tumors or CN... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003451-34 | Sponsor Protocol Number: intrusion | Start Date*: 2023-05-03 |
Sponsor Name:Erasmus Medical Center | ||
Full Title: INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 | ||
Medical condition: metastatic non-squamous non-small cell lung cancer metastatic estrogen positive breast cancer metastatic gastric cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003936-62 | Sponsor Protocol Number: PRONE | Start Date*: 2019-06-13 | ||||||||||||||||
Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE-IDIBELL | ||||||||||||||||||
Full Title: RENINE ANGIOTENSINE SYSTEM BLOCKADE (RAAS) IN RENAL TRANSPLANT RECIPIENTS WITH RENAL PROGENITOR CELLS (PEC's) IN URINE: RANDOMIZED CLINICAL TRIAL | ||||||||||||||||||
Medical condition: POST TRANSPLANT RENAL GLOMERULOPATHY | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005793-10 | Sponsor Protocol Number: 01012121 | Start Date*: 2021-07-08 | |||||||||||
Sponsor Name:Jakob Benedict Seidelin | |||||||||||||
Full Title: Open label Randomized Controlled clinical Trial of vedolizumab versus conventional treatment for Checkpoint Inhibitor induced Colitis | |||||||||||||
Medical condition: Immune check point inhibitor induced colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002192-18 | Sponsor Protocol Number: PrucaloprideRNAseq | Start Date*: 2018-09-14 |
Sponsor Name:KU Leuven | ||
Full Title: Characterization of nerve-modulated macrophage population in the gastrointestinal tract | ||
Medical condition: Patients undergoing colorectal surgery due to benign or malignant carcinoma, diverticulitis or constipation drug will be used to differentiate between macrophages that are modulated by enteric neu... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003797-32 | Sponsor Protocol Number: M14-172 | Start Date*: 2016-01-25 |
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||
Full Title: A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITI... | ||
Medical condition: Chronic Hepatitis C Infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002087-17 | Sponsor Protocol Number: M13-590 | Start Date*: 2015-10-29 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) | |||||||||||||
Medical condition: HCV Genotype 1 and HCV Genotype 1/HIV-1 co-infected subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PT (Completed) BE (Completed) AT (Completed) SE (Completed) DE (Completed) LT (Completed) ES (Completed) PL (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001120-54 | Sponsor Protocol Number: SQ167015 | Start Date*: 2016-07-25 |
Sponsor Name:University Hospitals Coventry and Warwickshire NHS Trust | ||
Full Title: Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage? | ||
Medical condition: Recurrent miscarriage | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002604-27 | Sponsor Protocol Number: PCT2017-1 | Start Date*: 2017-10-03 | |||||||||||
Sponsor Name:Department of Clinical Physiology, Nuclear Medicin and PET | |||||||||||||
Full Title: Phase II trial: RGD PET/MRI in sporadic Vestibular Schwannoma | |||||||||||||
Medical condition: Vestibularis Schwannoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004355-33 | Sponsor Protocol Number: MH002-UC-201 | Start Date*: 2021-09-23 | |||||||||||
Sponsor Name:MRM Health NV | |||||||||||||
Full Title: Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Mechanistic Effects, and Effects on Disease Activity of MH002 in Subjects with Mild to Moderate Ulcerative Colitis: A First-in... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000523-40 | Sponsor Protocol Number: HAI115879 | Start Date*: 2012-09-11 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Devlopment Ltd | |||||||||||||
Full Title: A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of G... | |||||||||||||
Medical condition: Hepatitis C virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
